Celltrion Pharm Inc Capital Reinvestment Ratio
Celltrion Pharm Inc capital reinvestment ratio. Celltrion Pharm Inc (068760) has a Capital Reinvestment Ratio of 0.10x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩23.44 Billion) in capital expenditures (₩2.27 Billion). See free cash flow generation of Celltrion Pharm Inc to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Celltrion Pharm Inc (2014–2024)
Capital reinvestment ratio of Celltrion Pharm Inc from 2014 to 2024. This chart tracks Celltrion Pharm Inc's Capital Reinvestment Ratio across 8 annual periods. See Celltrion Pharm Inc (068760) flexibility index to measure the company's free cash flow as a share of total liabilities.
Celltrion Pharm Inc Capital Reinvestment Ratio by Year (2014–2024)
Celltrion Pharm Inc capital reinvestment ratio by year from 2014 to 2024. For the full cash flow conversion analysis, see Celltrion Pharm Inc (068760) cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.11x | ₩56.59 Billion | ₩5.98 Billion | ▼ -86.6% |
| 2023 | 0.79x | ₩8.76 Billion | ₩6.90 Billion | ▲ +487.0% |
| 2021 | 0.13x | ₩93.15 Billion | ₩12.50 Billion | ▼ -88.4% |
| 2020 | 1.16x | ₩36.25 Billion | ₩41.98 Billion | ▲ +5.8% |
| 2019 | 1.09x | ₩27.85 Billion | ₩30.49 Billion | ▲ +117.4% |
| 2018 | 0.50x | ₩14.31 Billion | ₩7.21 Billion | ▼ -85.4% |
| 2015 | 3.44x | ₩13.36 Billion | ₩45.97 Billion | ▲ +127.8% |
| 2014 | 1.51x | ₩17.33 Billion | ₩26.16 Billion | — |